June 20, 2022
1 min read
A recent study found that exposure to high concentrations of perfluoroalkyl and polyfluoroalkyl substances was associated with an increased risk for hypertension in midlife women.
Everyday products contain perfluoroalkyl and polyfluoroalkyl substances (PFAS), and some notable ones include nonstick cookware and waterproof mascara, according to researchers. If their findings are further confirmed, the researchers hypothesized that reducing PFAS could aid in the prevention of hypertension and lessen the global CVD burden. It was the top story in cardiology last week.
Another top story was about an association between the AstraZeneca COVID-19 vaccine and a slight increased risk for thromboembolic events. Researchers analyzed patients who received the AstraZeneca, Pfizer or Moderna COVID-19 vaccine in Denmark, Finland and Norway. The AstraZeneca vaccine was associated with the greatest increased rate of coagulation disorders, but the absolute risk was low, according to researchers.
Read these and more top stories in cardiology below:
Common endocrine-disrupting chemicals may drive incident hypertension in midlife women
Women exposed to higher concentrations of a class of endocrine-disrupting chemicals known as PFAS are at increased risk for incident hypertension, researchers reported. Read more.
Thromboembolic events observed with AstraZeneca COVID-19 vaccine; absolute risk small
An analysis of data registries from three countries showed the AstraZeneca vaccine was associated with small but increased rates of hospital contacts for thromboembolic coagulation disorders, especially for thrombocytopenia. Read more.
Preeclampsia, hypertension during pregnancy more than doubles long-term hypertension risk
A cohort of mostly Black women who developed a hypertensive disorder of pregnancy were 2.4 times more likely to develop hypertension 10 years later, data from a prospective study show. Read more.
Recommendations for genetic testing to prevent sudden cardiac death in athletes
Cardiologists should work with experienced centers performing genetic testing to identify and manage inherited cardiac conditions in young athletes and inform patients of risks and benefits, according to a new joint scientific statement. Read more.
Sacubitril/valsartan adherence varies by subgroup; uptitration not common
Adherence to Entresto (sacubitril/valsartan, Novartis) was relatively good, at about 86% of prescribed patients with heart failure, but adherence behaviors were found to vary across subgroups, according to data published in the European Journal of Heart Failure. Read more.